|
Identification of the SNPs and their Interaction with environmental factors in Esophageal Cancer in Tanzania |
Li Zhang, PhD |
Division of Hematology and Medical Oncology |
|
|
|
Metastatic escape mechanisms in TKI resistant lung cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
Prostate Cancer Foundation Young Investigator Award |
|
Division of Hematology and Medical Oncology |
|
|
|
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase III Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy vs Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Locally Advanced or Metastatic Non Small-Cell Lung Cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel with or without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Advanced Non-small Cell Lung Carcinoma |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase I Study of INC280 plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer. |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase 2 Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma (FLC) |
|
Division of Hematology and Medical Oncology |
|
|
|
CARAVAN: Checkpoint-Radiation-Vaccine Neoadjuvant Trial for Metastatic Prostate Cancer |
|
Division of Hematology and Medical Oncology, Helen Diller Family Comprehensive Cancer Center |
|
|
|
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
A Multicenter Phase I/II Trial of Abiraterone + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
The Prostate Cancer Clinical Trials Consortium: Clinical Research Site Application |
|
Division of Hematology and Medical Oncology |
|
|
|
Serum Androgens as Predictors of Survival in Metastatic Prostate Cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
Patient Centered Videos to Enhance Informed Consent for Palliative Chemotherapy |
Katherine Van Loon, MD, MPH |
IGHS Faculty Affiliate, Division of Hematology and Medical Oncology |
|
|
|
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer |
Katherine Van Loon, MD, MPH |
IGHS Faculty Affiliate, Division of Hematology and Medical Oncology |
|
|
|
Dar es Salaam ESCC Case-Control Study |
Katherine Van Loon, MD, MPH |
Division of Hematology and Medical Oncology |
|
|
|
A Phase I/II Study Evaluating Microwave Hyperthermia and Thermodox (Lyso-Thermosensitive Liposomal Doxorubicin) in Patients with Breast Cancer Recurrence at the Chest Wall (DIGNITY) |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase II, Single Arm Study of the Use of Steroid-Based Mouthwash to Prevent Stomatitis in Postmenopausal Women with Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated with Everolimus plus Exemestane. |
|
Division of Hematology and Medical Oncology |
|
|
|
Open-Label, Expanded Access Protocol of BSI-201 in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available |
|
Division of Hematology and Medical Oncology |
|
|
|
Beacon (Breast Cancer Outcomes with Nktr-102): a Phase 3 Study of Nktr-102 Versus Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline, Taxane and Capecitabine |
|
Division of Hematology and Medical Oncology |
|
|
|
Enhancing the Efficacy of Chemotherapy in Triple Negative/Basal-like Breast Cancer by Targeting Macrophages |
|
Division of Hematology and Medical Oncology |
|
|
|
A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence |
|
Division of Hematology and Medical Oncology |
|
|
|
Master Member Agreement: Translational Breast Cancer Research Consortium |
|
Division of Hematology and Medical Oncology |
|
|
|
BEACON Study (BrEAst Cancer Outcomes with NKTR-102): Phase 3 Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with Anthracycline, a Taxane and Capecitabine |
|
Division of Hematology and Medical Oncology |
|
|
|
Cellular mechanisms of resistance to chemotherapy and the impact of immune modulating therapy, and molecular characterization of circulating tumor cells (CTCs) in patients with advanced breast cancer (ABC) |
|
Division of Hematology and Medical Oncology |
|
|
|
The Breast Cancer Clinical Trials Consortium |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene |
|
Division of Hematology and Medical Oncology |
|
|
|
Genetic Determinants of Capecitabine Toxicity |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase III Study Evaluating Palbociclib (PD-0332991), a Cycline-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone-Receptor-Positive, HER2-Normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy "Penelope" |
|
Division of Hematology and Medical Oncology |
|
|
|
Chronic Effects of Chemotherapy on Brain Function |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase 1b, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, A Humanized 1gG1 Antibody in Combination with Bevacizumab with or without Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase 1 Open-Label First-in-Human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Malignancies That Are Refractory to All Standard |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK) in Patients with Advanced Cancer |
|
Division of Hematology and Medical Oncology |
|
|
|
The role of HDAC2 in hormone therapy resistance |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase I Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients with Advanced Solid Tumors |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase 1B, Multi-Center, Open Label, Dose Escalation Study of Oral LDE225 in Combination with BKM120 in Patients with Advanced Solid Tumors |
|
Division of Hematology and Medical Oncology |
|
|
|
An Open-label, Multi-center, Extension Study of NKTR 102 in Subjects Previously Enrolled in NKTR-102 Studies |
|
Division of Hematology and Medical Oncology |
|
|
|
Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
|
Division of Hematology and Medical Oncology |
|
|
|
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects with Solid Tumors or Lymphoma |
|
Division of Hematology and Medical Oncology |
|
|
|
Sanofi-Aventis SAR650894 Program - Research Component |
|
Division of Hematology and Medical Oncology |
|
|
|
Real-World Treatment Patterns and Associated Outcomes Among Patients with Advanced Progressive Pancreatic Neuroendocrine Tumors |
|
Division of Hematology and Medical Oncology |
|
|
|
A Pilot Study of FOLFOX in Combination with Bevacizumab in Patients with Advanced Neuroendocrine Tumors |
|
Division of Hematology and Medical Oncology |
|
|
|
Identification of the CD8+ Cell Anti-HIV Factor (CAF) |
|
Division of Hematology and Medical Oncology, AIDS Research Institute |
|
|
|
Subcontract from UFL Prime: HIV/FIV-Cat-Model: A model to identify vaccine epitopes |
|
Division of Hematology and Medical Oncology, AIDS Research Institute |
|
|
|
Role of Innate Immunity in Controlling HIV Infection |
|
Division of Hematology and Medical Oncology, AIDS Research Institute |
|
|
|
HIV cure with CCR5 (-) human IPS hematopoietic stem cells |
|
Division of Hematology and Medical Oncology |
|
|
|
HIV cure with CCR5 negative human IPS hematopoietic stem cells |
|
Division of Hematology and Medical Oncology, AIDS Research Institute |
|
|
|
Role of Innate Immunity in Controlling HIV Infection |
|
Division of Hematology and Medical Oncology, AIDS Research Institute |
|
|
|
Chinese Fellowship |
|
Division of Hematology and Medical Oncology |
|
|
|
Protection from HIV Infection in Intravenous Drug Users |
|
Division of Hematology and Medical Oncology |
|
|
|
UCSF AIDS Research Training Program |
|
Division of Hematology and Medical Oncology |
|
|
|
JCF/Bransten Grant |
|
Division of Hematology and Medical Oncology, AIDS Research Institute |
|
|
|
Identification of the CD8 Cell Anti-HIV Factor (CAF) |
|
Division of Hematology and Medical Oncology |
|
|
|
Immunologic and Virologic Features of Early HIV Infection |
|
Division of Hematology and Medical Oncology |
|
|
|
Role of Innate Immunity in Controlling HIV Infection |
|
Division of Hematology and Medical Oncology, AIDS Research Institute |
|
|
|
Identification of the CD8+ Cell Antiviral Factor (CAF) |
|
Division of Hematology and Medical Oncology, AIDS Research Institute |
|
|
|
Molecular Epidemiology of the Human Immunodeficiency Virus in Mexico |
|
Division of Hematology and Medical Oncology |
|
|
|
Role of Innate Immunity in Controlling HIV Infection |
|
Division of Hematology and Medical Oncology |
|
|
|
Innate Immunity and Autophagy in Elite Controllers |
|
Division of Hematology and Medical Oncology |
|
|
|
AIDS Malignancies Consortium |
Lawrence Kaplan, MD |
Division of Hematology and Medical Oncology |
|
|
|
Compassionate Use of Marqibo for the Treatment of Refractory T-Cell Acute Lymphoblastic Leukemia |
Lawrence Kaplan, MD |
Division of Hematology and Medical Oncology |
|
|